ClinicalTrials.gg

Program

licaminlimab

Also written as “LME636 60 mg/mL ophthalmic solution” and “LME636 ophthalmic solution”.

Its studies are mostly in Dry Eye Syndromes · Uveitis, Anterior, led by 3 companies.

Furthest: phase 3, since Apr 16, 20264 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Oculis21 open or runningphase 3since Apr 16, 2026May 31, 2023Dec 2026phase 3 · NCT07548632
Alcon10 open or runningphase 2since Jun 23, 2015Jun 23, 2015none ahead
Novartis10 open or runningphase 2since Feb 13, 2015Feb 13, 2015none ahead

Also a collaborator on its studies: ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2015First study: phase 2 study in Dry Eye SyndromesNew to NovartisNovartis · NCT02365519 · 514 enrolled
  2. Jun 23, 2015Alcon's first study: phase 2 study in Uveitis, AnteriorNew to AlconAlcon · NCT02482129 · 45 enrolled
  3. May 31, 2023Oculis's first study: phase 2 study in Dry Eye SyndromesNew to OculisOculis · NCT05896670 · 122 enrolled · United States
  4. Apr 16, 2026Phase 3 study in Dry Eye SyndromesPhase 3 reachedOculis · NCT07548632 · 160 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Dry Eye SyndromesOculis · NCT07548632

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07548632Dry Eye Syndromes · United States3Active, not recruitingOculisDec 2026160
NCT05896670Dry Eye Syndromes · United States2CompletedOculisMar 27, 2024122
NCT02482129Uveitis, Anterior2CompletedAlconMar 21, 201645
NCT02365519Dry Eye Syndromes2CompletedNovartisOct 16, 2015514

How it is read

Names in the registry

  • “licaminlimab”, 2 entries
  • “LME636 60 mg/mL ophthalmic solution”, 1 entry
  • “LME636 ophthalmic solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.